Skip to main content

Table 2 Clinical-epidemiological features of our validation series of 561 patients

From: An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external‐beam radiotherapy

Clinical characteristics

 

Follow-up, mo

 

Mean (SD)

56.5 (27.7)

Median (min–max)

50 (3–146)

Age, yy

 

Mean (SD)

71.9 (5.7)

Median (min–max)

73 (51–88)

PSA, ng/mL

 

Mean (SD)

12.93 (30.96)

Median (min–max)

7.70 (1.14–680)

T staging, no (%)

 

cT1

355 (63%)

cT2

182 (33%)

cT3-4

24 (4%)

bGS, no (%)

 

 ≤ 6

220 (39%)

3 + 4

174 (31%)

4 + 3

69 (12%)

8

55 (10%)

9–10

43 (8%)

Biopsy cores sampled, no

 

Mean (SD)

11.0 (4.6)

Median (min–max)

10 (2–35)

%PC, %

 

Mean (SD)

41.3% (27.8)

Median (min–max)

38% (4–100)

N staging, %

 

Not performed

72%

performed N0

27.3%

performed N1

0.7%

M staging, %

 

Not performed

74%

performed M0

26%

D’Amico risk class, no (%)

 

Low

119 (21%)

Intermediate

223 (40%)

High

219 (39%)

Candiolo risk class, no (%)

 

Very-low

133 (24%)

Low

211 (37%)

Intermediate

133 (24%)

High

56 (10%)

Very-high

28 (5%)

RT dose to prostate-CTV, ED2Gy, α/β = 2,5

 

Mean (SD)

77.7 (2.4)

Median (min–max)

78 (72–82)

Fractionation schedule, %

 

Std fractionation 2 Gy /fr

77%

Hypo-fractionation 2,7 Gy /fr

23%

RT technique, %

 

3DCRT

77%

IMRT-IGRT

23%

Seminal vesicles irradiation, %

 

No

22%

Yes

78%

Pelvic nodal irradiation, %

 

No

98%

Yes

2%

Exclusive RT

24%

RT + ADT

76%

ADT duration, mo

 

Mean (SD)

13.0 (10.1)

Median (min–max)

8 (1–46)

ADT drug, %

 

Anti-Androgen

37%

LHRH-analogue

49%

TAB

14%

  1. SD, standard deviation; ED2Gy, equivalent dose at standard dose of 2 Gy per fraction; RT, radiotherapy; ADT, androgen deprivation therapy